Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

Next Previous
X
Search
Trial Profile

A Phase I/II Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LAE 001 (Primary) ; Antiandrogens
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Laekna Therapeutics

    • Most Recent Events

    • 20 Feb 2024 Status changed from recruiting to suspended.
    • 21 Sep 2021 Results (As of Feb 28, 2021; n=17) assessing safety of LAE001 in patients with metastatic castration-resistant prostate cancer, presented at the 46th European Society for Medical Oncology Congress
    • 16 Sep 2021 According to a Laekna Therapeutics media release, patient enrollment of the Phase II trial is expected to start between the fourth quarter of 2021 and the first quarter of 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top